Tesla
TSLA
NVIDIA
NVDA
Palantir
PLTR
4
Apple
AAPL
5
Advanced Micro Devices
AMD
US Stock MarketDetailed Quotes
AKBA Akebia Therapeutics
- 1.8894
- +0.0294+1.58%
Trading Mar 11 11:50 ET
412.23MMarket Cap-8.59P/E (TTM)
1.9000High1.8200Low1.26MVolume1.8300Open1.8600Pre Close2.33MTurnover0.59%Turnover RatioLossP/E (Static)218.18MShares2.480052wk High-8.18P/B401.38MFloat Cap0.800052wk Low--Dividend TTM212.44MShs Float31.0000Historical High--Div YieldTTM4.30%Amplitude0.2410Historical Low1.8490Avg Price1Lot Size
Akebia Therapeutics Stock Forum
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
8. With regards ...
Akebia Therapeutics Announces Multiple Positive Business Updates
Akebia Therapeutics (NASDAQ: AKBA) announced significant business updates regarding Vafseo® (vadadustat), its treatment for anemia in chronic kidney disease (CKD) patients on dialysis. The company has secured commercial supply contracts covering nearly 100% of U.S. dialysis patients and commenced product shipments in January 2025.
Market research indicates strong physician interest, with 99% of n...
No comment yet